Patent SG-11201900163P-A (SG)
Title: Macrocycle kinase inhibitors
Inventor: CUI JINGRONG JEAN
IPC: C07D498/12
Filed: 2017-07-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI HIM 011101 0 01111011MM vu 1111110 HOED Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/022911 Al 01 February 2018 (01.02.2018) W I P0 I P C T (51) International Patent Classification: Declarations under Rule 4.17: A61K 31/519 (2006.01) C07D 498/02 (2006.01) CO7D 487/04 (2006.01) CO7D 498/12 (2006.01) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/US2017/044214 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 27 July 2017 (27.07.2017) — with international search report (Art. 21(3)) — (25) Filing Language: English before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (26) Publication Language: English amendments (Rule 48.2(h)) (30) Priority Data: 62/367,886 28 July 2016 (28.07.2016) US (71) Applicant: TP THERAPEUTICS, INC. [US/US]; 10628 Science Center Drive, Ste. 225, San Diego, California 92121 (US). (72) Inventors: CUI, Jingrong Jean; 10628 Science Center Drive, Ste. 225, San Diego, California 92121 (US). LI, Yis- han; 10628 Science Center Drive, Ste. 225, San Diego, Cal- ifornia 92121 (US). ROGERS, Evan W.; 10628 Science — Center Drive, Ste. 225, San Diego, California 92121 (US). = ZHAI, Dayong; 10628 Science Center Drive, Ste. 225, San Diego, California 92121 (US). UNG, Jane; 10628 Science = Center Drive, Ste. 225, San Diego, California 92121 (US). — = (74) Agent: LIPTAK, Vincent P.; BARNES & THORNBURG LLP, 11 South Meridian Street, Indianapolis, Indiana 46204 (US). Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, = = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, _ KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = MG, MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every (84) = — kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = — 1-1 1-1 1-1 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). cT ei ei © —.... 00 1-1 (54) Title: MACROCYCLE KINASE INHIBITORS 0 ei (57) : The present disclosure relates to certain macrocyclic kinase inhibitors, pharmaceutical compositions containing the 0 same, and methods of using the same to treat disease.